Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This is a single arm multi-centre NCRI feasibility study of CHOP combined with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter’s syndrome.

Phase II single arm multi-centre NCRI feasibility study of CHOP combined with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter’s syndrome.  

Objectives

Primary:

  • Evaluate overall response rate (ORR) to CHOP-O according to the Revised Response Criteria for Malignant Lymphoma (Cheson criteria).

Secondary:

  • Feasability of recruitment.
  • Progression free survival (PFS).
  • Overall Survival (OS).
  • The clinical benefit and changes in patient reported outcome measures (PRO).
  • Safety and tolerability.

 

For the published paper please click here

 

 

Our team

  • Sarah Pearson

    OCTO Trial Management Director